Skip to content

Randomised multicentre trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson*s disease

Randomised multicentre trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson*s disease - N-STAPS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30282
Enrollment
128
Registered
2006-06-01
Start date
2007-02-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

A neurosurgical procedure using stereotactic techniques will be employed for implantation of two electrodes with the functional contact at both subthalamic nuclei or both globus pallidus. The electr

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are idiopathic Parkinson's disease and * despite optimal pharmacological treatment * at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonias, or bradykinesia.

Exclusion criteria

Exclusion criteria: Exclusion criteria are: age below 18 years, previous functional stereotactic neurosurgery, Hoehn and Yahr stage 5 at the best moment during the day, a MATTIS dementia rating scale score of 120 or less, current psychosis or depression, and contraindications for stereotactic neurosurgery such as a physical disorder making surgery hazardous (severe hypertension, blood coagulation disorder, severe dysphagia, or dysarthria).

Design outcomes

Primary

MeasureTime frame
Baseline and outcome measurements at 12 months will be done in standardized off and on phases. The primary outcome measures are the Neuropsychiatric Inventory (cognition, mood, and behavior) and the off-on phase weighted AMC Linear Disability Scale (functional improvement).

Secondary

MeasureTime frame
Secondary outcome consists of symptom scales, activities of daily living scales, a quality of life questionnaire, adverse effects, and medication use. Additionally, patients will undergo extensive neuropsychological assessment.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)